Ceribell CTO’s 10b‑5‑1 Trades Spark Debate: Big Buys at $2.24, Massive Sales at $18+ in One Day

Insider Trading Pulse at Ceribell Inc.

Rule‑10b5-1 Plan Moves in a Volatile Market On March 2 2026, Chief Technology Officer Woo Raymond executed a series of Rule‑10b5‑1 trades that illustrate both the utility and the scrutiny of pre‑planned insider transactions. The plan, adopted on May 28 2025, allowed Raymond to buy 1,472 shares at $2.24, sell 1,472 shares at an average of $18.26, and purchase larger blocks of 3,025 and 6,615 shares at $4.70 each. These transactions were followed by a sale of 6,615 shares at $18.25, and a series of option‑related sell orders. The timing is notable: the trades were conducted when the market price hovered around $17.77, a point that sits near the 52‑week low, yet still above the one‑month average. While the moves are technically compliant, the pattern—large buys early in the trading window and sales later in the day—raises questions about market timing and the potential use of insider knowledge even within a formal plan.

Implications for Investors and Company Outlook The volume of shares traded under the plan (over 20,000 shares in a single day) suggests a significant capital allocation by the CTO, which can be interpreted in two ways. First, large purchases may signal confidence in Ceribell’s product pipeline, particularly the AI‑driven Clarity algorithm and the expanding EEG portal, which could drive revenue growth. Second, the concurrent sales at higher prices could reflect a strategic liquidity event, perhaps to fund R&D or to balance the company’s capital structure amid a declining share price that has fallen 19.76 % year‑to‑date. For shareholders, the net effect is a dilution of shares held by insiders, potentially exerting downward pressure on the stock. However, the CTO’s consistent participation in the plan—across 2025 and early 2026—indicates a long‑term commitment that may assuage short‑term concerns.

Woo Raymond: A Profile of Consistent Activity Reviewing Raymond’s historical filings shows a pattern of disciplined trading: he routinely executes both purchases and sales under the 10b5‑1 plan, often aligning buys with low market valuations (e.g., $2.24 in December 2025) and sells near peaks (e.g., $20.57 in February 2026). His option sales—many of which occur at the vesting date—suggest a preference for converting equity awards into cash rather than retaining them. Compared to peers such as CEO Chao Xingjuan, whose trading volume is higher but less predictable, Raymond’s activity is methodical and tied to a fixed schedule. This predictability may reassure investors that the CTO is not exploiting material non‑public information, but it also means that any price movements around the plan’s execution windows could become catalysts for volatility.

Market Context and Forward Look Ceribell’s stock has been highly volatile, swinging from $10.01 in April 2025 to $24.33 in January 2026. The recent dip to $17.54 on March 2 2026 reflects broader market softness in healthcare tech. The insider activity, occurring just as the share price approaches a 52‑week low, could signal an attempt to capitalize on a perceived undervaluation. Looking forward, the company’s product roadmap—including the expansion of its seizure‑detection AI and potential regulatory approvals—could justify a rally. However, investors should watch for subsequent insider transactions, especially those by other executives, as a gauge of management confidence. In the meantime, the 10b5‑1 trades by Woo Raymond underscore the delicate balance between insider confidence and market perception in a highly cyclical sector.